The effects on bone metabolism in patients using hydroxychloroquine

The effects on bone metabolism in patients using hydroxychloroquine - HCQ and bone metabolism

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42271

Enrollment

Registered

2015-06-30

Start date

2015-07-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age > 18 years Patients with pSS, sarcoidosis, RA or SLE who start with HCQ

Exclusion criteria

Exclusion criteria: Other underlying auto-immune disease Use of medications against osteoporosis (e.g. bisphosphonates) Severe vitamin D deficiency (serum level 7.5 mg for > 3 months in the last year) Multiple myeloma Mastocytosis

Design outcomes

Secondary

Measure	Time frame
To evaluate the change in serum PINP and BAP in patients who start with HCQ treatment	—

Primary

Measure	Time frame
The main outcome of this study is to evaluate the changes in beta-CTX due to HCQ treatment.	—

Countries

Netherlands

Outcome results